Literature DB >> 32873411

Commentary: Neoadjuvant treatment of resectable pancreatic cancer: Lack of level III evidence.

Martin Schneider1, John P Neoptolemos1, Markus W Büchler2.   

Abstract

Entities:  

Mesh：

Year:  2020        PMID： 32873411     DOI： 10.1016/j.surg.2020.07.033

Source DB:  PubMed          Journal:  Surgery        ISSN： 0039-6060            Impact factor:   3.982


× No keyword cloud information.
  3 in total

Review 1.  Resection of Recurrent Pancreatic Cancer: Who Can Benefit?

Authors:  Henrik Nienhüser; Markus W Büchler; Martin Schneider
Journal:  Visc Med       Date:  2021-11-11

2.  Pre-operative radiomics model for prognostication in resectable pancreatic adenocarcinoma with external validation.

Authors:  Gerard M Healy; Emmanuel Salinas-Miranda; Rahi Jain; Xin Dong; Dominik Deniffel; Ayelet Borgida; Ali Hosni; David T Ryan; Nwabundo Njeze; Anne McGuire; Kevin C Conlon; Jonathan D Dodd; Edmund Ronan Ryan; Robert C Grant; Steven Gallinger; Masoom A Haider
Journal:  Eur Radiol       Date:  2021-11-10       Impact factor: 7.034

Review 3.  Neoadjuvant chemotherapy with or without radiotherapy versus upfront surgery for resectable pancreatic adenocarcinoma: a meta-analysis of randomized clinical trials.

Authors:  I Ghanem; D Lora; N Herradón; G de Velasco; A Carretero-González; M Á Jiménez-Varas; P Vázquez de Parga; J Feliu
Journal:  ESMO Open       Date:  2022-05-14
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.